文献速递主动脉疾病

低剖面Zenith Alpha胸主动脉支架单中心中期结果

Single-center midterm results with the low-profile Zenith Alpha thoracic endovascular stent graft.
PubMed 文献 · J Vasc Surg · 2020-10-14

单中心回顾性分析262例患者270次Zenith Alpha胸主动脉腔内修复术,30天临床成功率92.6%,5年生存率88.5%,无支架骨折或移植物迁移导致的新发I型内漏,中期结果满意。

要点

  • 30天临床成功率92.6%,择期与急诊死亡率差异显著(2.5% vs 30.8%)
  • 经皮入路股动脉并发症率5.1%,需外科转换1.9%
  • 5年无支架骨折或迁移相关新发I型内漏,二次干预率5.3%

核心结论

  • 新一代低剖面胸主动脉支架的中期结果满意,二次干预率低且无支架迁移,提示长期耐久性良好。

主要发现

  • 总体30天死亡率为5.2%,择期病例为2.5%,非择期病例为30.8%。
  • 30天主要技术成功率为97.8%,临床成功率为92.6%。
  • 经皮入路占58.5%,股动脉并发症率为5.1%,需外科转换率为1.9%。
  • 卒中率为4.1%(主要卒中2.2%),脊髓缺血率为3.7%(永久性截瘫0.7%)。
  • 总体随访生存率1年94.0%、2年91.6%、3年88.9%、5年88.5%,非计划二次血管内手术率为5.3%,未观察到支架骨折或支架迁移导致的新发I型内漏。

临床怎么用

  • 低剖面设计可能减少入路并发症,但需注意择期与急诊病例的死亡率差异。
  • 中期随访中无支架迁移和新发I型内漏,支持该支架用于胸主动脉疾病的耐久性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The analysis of endovascular treatment of thoracic aortic diseases using new low-profile stent grafts in large series is crucial to understanding the durability of these devices. The present study reports the midterm outcomes of a single-center experience using the Zenith Alpha thoracic endovascular stent graft. METHODS: The outcomes of 270 procedures performed on 262 patients (197 men; mean age, 70.5 ± 9.5 years) using the Zenith Alpha thoracic endovascular stent graft from November 2013 to December 2019 for different thoracic aortic diseases were analyzed. The primary endpoints were 30-day clinical success and midterm (5-year) clinical success. The secondary endpoints were the adverse event rate at 30 days and midterm and access- and device-related complications. The follow-up of surviving patients was performed using computed tomography angiography and office visits at 1, 6, and 12 months and annually thereafter. Kaplan-Meier analysis was performed for overall survival, and freedom from thoracic aortic endovascular repair-related mortality and related reinterventions. RESULTS: The overall 30-day mortality was 5.2% (2.5% for elective and 30.8% for nonelective cases). Type I endoleaks were identified in six patients. The 30-day primary technical and clinical success rates were 97.8% and 92.6%, respectively. Femoral cutdown was used in 41.1% of cases and percutaneous access in 58.5%. The rate of femoral artery complications after the percutaneous approach was 5.1%, with the need for surgical conversion in 1.9%. The stroke rate was 4.1% (major stroke, 2.2%), and the spinal cord ischemia rate was 3.7% (permanent paraplegia, 0.7%). Of the 248 survivors, 239 complied with the follow-up protocol with adequate computed tomography angiograms available images. Overall follow-up survival was 94.0% at 1 year, 91.6% at 2 years, 88.9% at 3 years, and 88.5% at 5 years. The unplanned secondary endovascular procedure rate was 5.3%. No stent fractures or new-onset type I endoleaks due to stent graft migration were observed in the study cohort. CONCLUSIONS: The midterm outcomes of this new generation of low-profile devices were satisfactory. The reported low incidence of secondary procedures and the absence of migrations are promising for the long-term durability of these devices.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Melissano G, Rinaldi E, Mascia D, et al. Single-center midterm results with the low-profile Zenith Alpha thoracic endovascular stent graft. J Vasc Surg. 2020. PMID: 33065242. doi:10.1016/j.jvs.2020.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。